# Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

> **NCT04566393** · — · AVAILABLE · sponsor: **xCures**

## Conditions studied

- Pancreatic Cancer
- Small Bowel Cancer
- Colorectal Cancer
- Melanoma
- Non Small Cell Lung Cancer
- Thyroid Cancer
- Bladder Cancer
- Head and Neck Cancer
- Gastric Cancer
- Esophageal Cancer
- Cholangiocarcinoma
- Ovarian Cancer
- Hepatocellular Carcinoma
- Glioblastoma
- MAPK Gene Mutation
- KRAS Activating Mutation
- BRAF Gene Mutation
- NRAS Gene Mutation
- HRAS Gene Mutation
- MEK Mutation
- ERK Mutation

## Interventions

- **DRUG:** Ulixertinib (BVD-523)

## Key facts

- **NCT ID:** NCT04566393
- **Lead sponsor:** xCures
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566393, "Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04566393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*